Skip to main content

Psoriatic arthritis

Rheumatology Round-Up with Drs. Kavanaugh & Cush

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

RT @vksandhumd: Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador http

Vaneet K Sandhu, MD vksandhumd

3 weeks 4 days ago
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies

Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.

Mid-Meeting Recap: Psoriatic Arthritis

On Saturday, November 7th, Drs. Cush and Kavanaugh discuss psoriatic arthritis reports from ACR 2020 with Dr. Eric Ruderman and Dr. Robert Chao.

Enthesitis in PsA: Dr. Robert Chao

Dr. Robert Chao reviews abstracts #1853, #1552, #1543 and #2021 presented at the 2020 ACR annual meeting. 

 

 

RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,

Robert B Chao, MD doctorRBC

3 weeks 5 days ago

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Who has more comorbidities? Dr. Janet Pope

Dr. Janet Pope reviews abstract #1466 presented at the 2020 ACR annual meeting. Who has more comorbidities: OA, Gout, RA or PsA? 

RT @doctorRBC: Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO

Robert B Chao, MD doctorRBC

3 weeks 5 days ago
Deucravacitinib TYK2i for PsA Phase2b 16wk, Double-blind, Placebo, RCT ⬆️ACR20/50/70 response vs. PBO ⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO *⃣No serious AE @RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial o

Dr. John Cush RheumNow

3 weeks 5 days ago
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
RT @doctorRBC: Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you r

Robert B Chao, MD doctorRBC

3 weeks 5 days ago
Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you routinely use MRI to monitor disease activity in your PsA patients? @RheumNow #ACR20
×